American Association for Cancer Research
Browse
ccr-21-4554_table_s4_suppts4.docx (17.16 kB)

Supplementary Table from Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck

Download (17.16 kB)
journal contribution
posted on 2023-03-31, 23:41 authored by Jennifer L. Leddon, Shuchi Gulati, Sulsal Haque, Casey Allen, Sarah Palackdharry, Maria Mathews, Nicky Kurtzweil, Muhammed Kashif Riaz, Vinita Takiar, Misako Nagasaka, Yash Patil, Chad Zender, Alice Tang, Brian Cervenka, Julie McGrath, W. Michael Korn, Benjamin H. Hinrichs, Roman Jandarov, Nusrat Harun, Ammar Sukari, Trisha M. Wise-Draper
Supplementary Table from Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck

Funding

The University of Cincinnati Post-Doctorate Heme-Onc Translational Training Grant

National Center for Advancing Translational Sciences of the NIH

Research Scholars Grant

Career Development Award

National Institute on Drug Abuse

Find out more...

History

ARTICLE ABSTRACT

Locoregional relapse in patients with head and neck squamous cell carcinoma (HNSCC) is common, approaching 50% for some subsites despite multimodality therapy. Salvage surgery is the standard of care, but able to achieve durable control in only a minority of patients. While adjuvant radiotherapy or chemo-radiotherapy is offered to select patients, this approach can be prohibitively toxic. Given the activity and tolerability of programmed death-1 inhibitors in metastatic HNSCC, we investigated the safety and efficacy of adjuvant nivolumab after salvage surgical resection. This was an open-label, multi-institutional phase II clinical trial (NCT03355560). Patients with recurrent, resectable HNSCC were enrolled within 6 weeks of salvage surgery. Six 28-day cycles of adjuvant nivolumab were planned. The primary endpoint was 2-year disease-free survival (DFS) more than 58%, based on an institutional historical control group of 71 patients with recurrent HNSCC who underwent salvage surgery. Between February 2018 and February 2020, 39 patients were enrolled. At a median follow-up of 22.1 months, 2-year DFS was 71.4% [95% confidence interval (CI), 57.8–88.1] and the 2-year overall survival (OS) was 73% (95% CI, 58–91.8). Three of 39 (8%) patients experienced grade 3 treatment-related adverse events and 3 of 39 (8%) discontinued treatment due to side effects. Ten of 39 had locoregional recurrence, while 2 of 10 also had synchronous metastatic disease. There was no difference in DFS between PD ligand-1 (PD-L1)–positive and PD-L1–negative patients. There was a nonsignificant trend toward improved DFS in patients with high tumor mutational burden (P = 0.083). Adjuvant nivolumab after salvage surgery in locally recurrent HNSCC is well tolerated and showed improved DFS compared with historical controls.

Usage metrics

    Clinical Cancer Research

    Categories

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC